Fortress Companies

Home » Fortress companies » journey medical

Journey Medical Corporation

Journey Medical Corporation (JMC) is a subsidiary of Fortress Biotech, Inc. formed in October 2014. JMC is an innovative company focused on developing, acquiring, licensing, and commercializing branded dermatology products.  Journey launched seven products since 2016; four products under the Journey name and three products under a co-promote agreement.

In Q4 2018, Journey launched Exelderm®, a cream and solution for fungal infections. Also in 2018, Journey signed an agreement with Crown Labs to promote Triderm, a topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Ala-quin®, a cream for mixed infections, and Ala-scalp®, a hydrocortisone lotion for corticosteroid-responsive dermatoses. In Q4 2016, Journey launched Targadox®, a 50 mg immediate-release doxycycline hyclate film-coated tablet.  Targadox is indicated as adjunctive therapy for severe acne.  In 2016, Journey also launched Luxamend® Wound Cream and Ceracade® Skin Emulsion. 

JMC is headquartered in Scottsdale, Arizona and is led by President and CEO, Claude Maraoui. Claude has more than 25 years of experience in commercializing dermatology products.  He was previously Vice President of Dermatology Sales at Medicis with a proven track record of success in leadership positions within the Sales & Marketing functions of both the prescription therapy and aesthetic businesses. 

Fortress Biotech currently owns >50% of Journey Medical Corporation.

For more information, please visit: www.jmcderm.com